Replimune Group, Inc. (REPL)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Philip Astley-Sparke F.S.A. | Executive Chairman | 960.52k | -- | 1971 |
| Ms. Emily Luisa Hill | Chief Financial Officer | 593.05k | -- | 1980 |
| Dr. Konstantinos Xynos M.B.A., M.D., Ph.D. | Chief Medical Officer | 668.69k | -- | 1967 |
| Dr. Sushil Patel Ph.D. | CEO & Director | 665.05k | -- | 1971 |
| Dr. Robert Coffin Ph.D. | Founder, Chief Scientist & Director | 785.89k | -- | 1965 |
| Mr. Andrew Schwendenman | Chief Accounting Officer & Treasurer | -- | -- | 1976 |
| Mr. Christopher Sarchi | Chief Commercial Officer | -- | -- | 1969 |
| Mr. Paul Bullock | Chief Manufacturing Officer & Framingham Site Head | -- | -- | -- |
Replimune Group, Inc.
- Sector:?
- Healthcare
- Industry:? Biotechnology
- Full Time Employees:?
- 331
Description
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
Corporate Governance
Upcoming Events
November 5, 2024 at 1:30 PM UTC - November 11, 2024 at 1:30 PM UTC
Replimune Group, Inc. Earnings Date
Recent Events
August 13, 2024 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission